Exploration of the barriers and enablers of benzodiazepines deprescribing in prisons: A qualitative study among health and social care professionals.
benzodiazepines
deprescribing
prison
qualitative research
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
revised:
26
05
2023
received:
26
01
2023
accepted:
30
05
2023
pubmed:
5
6
2023
medline:
5
6
2023
entrez:
5
6
2023
Statut:
aheadofprint
Résumé
The prison environment is a place of high consumption of benzodiazepines (BZDs) due to the anxiety and sleep disturbances, mental disorders, detoxification and trafficking. The study aims to explore experiences of health and social care professionals on the use of BZDs in prisons, as well as the barriers and enablers to their deprescribing. Semistructured individual interviews with professionals working in a prison setting were performed between March and April 2022, based on an interview guide. They were recorded and transcribed using the NVivo software. A qualitative analysis using an inductive approach based on a thematic analysis was performed. Sixteen health professionals were interviewed, including psychiatrists, general practitioners, nurses, pharmacists, psychologists, musicologists and pharmacy technicians. The identified barriers to deprescribing BZDs were problems of coordination between prescribers, lack of time and alternatives. Concerning the enablers, therapeutic education groups, staff's awareness of the irrelevance of some medication and multi-professional advice were identified. This study highlights the similarities in deprescribing difficulties between prison and other settings. Some of the levers identified in our study have shown their effectiveness in different settings. Deprescribing is done most of the time in good conditions but requires an additional delay compared to the outside environment.
Sections du résumé
BACKGROUND
BACKGROUND
The prison environment is a place of high consumption of benzodiazepines (BZDs) due to the anxiety and sleep disturbances, mental disorders, detoxification and trafficking.
OBJECTIVE
OBJECTIVE
The study aims to explore experiences of health and social care professionals on the use of BZDs in prisons, as well as the barriers and enablers to their deprescribing.
METHOD
METHODS
Semistructured individual interviews with professionals working in a prison setting were performed between March and April 2022, based on an interview guide. They were recorded and transcribed using the NVivo software. A qualitative analysis using an inductive approach based on a thematic analysis was performed.
RESULTS
RESULTS
Sixteen health professionals were interviewed, including psychiatrists, general practitioners, nurses, pharmacists, psychologists, musicologists and pharmacy technicians. The identified barriers to deprescribing BZDs were problems of coordination between prescribers, lack of time and alternatives. Concerning the enablers, therapeutic education groups, staff's awareness of the irrelevance of some medication and multi-professional advice were identified.
DISCUSSION
CONCLUSIONS
This study highlights the similarities in deprescribing difficulties between prison and other settings. Some of the levers identified in our study have shown their effectiveness in different settings.
CONCLUSION
CONCLUSIONS
Deprescribing is done most of the time in good conditions but requires an additional delay compared to the outside environment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Références
Liu D, Zhang Q, Zhao Z, et al. Benzodiazepine-receptor agonist utilization in outpatients with anxiety disorder: a retrospective study based on electronic healthcare data from a large general tertiary hospital. Healthcare. 2023;11(4):554. doi:10.3390/healthcare11040554
ANSM. Etat Des Lieux de La Consommation de Benzodiazépines En France. 2017.
Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95-114. doi:10.1016/j.drugalcdep.2019.02.033
Verdoux H, Tournier M, Cougnard A, Martin K, Bégaud B. Pharmaco-épidémiologie des médicaments psychotropes: utilisation et impact en conditions réelles d'utilisation. Therapies. 2006;61(1):17-22. doi:10.2515/therapie:2006006
Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169. doi:10.1136/bmj.38623.768588.47
Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ. 2014;349(sep09 2):g5205. doi:10.1136/bmj.g5205
inserm-ec-2012-medicamentspsychotropesconsommationspharmacodependances-synthese.pdf. Médicaments psychotropes-consommations et pharmacodépendances. Accessed April 4, 2023. https://www.inserm.fr/wp-content/uploads/media/entity_documents/inserm-ec-2012-medicamentspsychotropesconsommationspharmacodependances-synthese.pdf
Barker M. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19(3):437-454. doi:10.1016/S0887-6177(03)00096-9
Agence Nationale de Sécurité du Médicament. Arrêt des benzodiazépines et médicaments apparentés: démarche du médecin traitant en ambulatoire. 2015. Accessed March 13, 2023. https://www.has-sante.fr/jcms/c_2038262/fr/arret-des-benzodiazepines-et-medicaments-apparentes-demarche-du-medecin-traitant-en-ambulatoire
Haute Autorité de Santé. Modalités d'arrêt Des Benzodiazépines et Médicaments Apparentés Chez Le Patient Âgé. 2007. Accessed February 26, 2021. https://www.has-sante.fr/upload/docs/application/pdf/arret_des_bzd_-_argumentaire.pdf
Agence Nationale de Sécurité du Médicament. Usage des médicaments de ville en France durant l'épidémie de Covid-19: point de situation jusqu'au 25 Avril 2021. 2021. Accessed March 13, 2023. https://ansm.sante.fr/uploads/2021/05/27/epi-phare-rapport-6-medicaments-covid-20210527.pdf
Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66(3):201-202. doi:10.4212/cjhp.v66i3.1261
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827. doi:10.1001/jamainternmed.2015.0324
deprescribing.org Déprescription des benzodiazépines et ‘Z-drugs” (BZRA)-notes. Accessed July 8, 2022. https://deprescribing.org/wp-content/uploads/2018/05/deprescribing-algorithm-benzodiazepines-2018-fr.pdf
Cabelguenne D, Picard C, Lalande L, et al. Benzodiazepine dose reduction in prisoner patients: 15 years' teamwork between psychiatrists and pharmacists. J Clin Pharm Ther. 2018;43(6):807-812. doi:10.1111/jcpt.12709
Lafortune D, Vacheret M. La prescription de médicaments psychotropes aux personnes incarcérées dans les prisons provinciales du Québec. Santé Ment au Qué. 2010;34(2):147-170. doi:10.7202/039130ar
Protais C, Morel d'Arlaux J, Jauffret-Roustide M. Usages de drogues en prison, Pratiques, conséquences et réponses. OFDT. Published online December 2019.
Rousselet M, Guerlais M, Caillet P, et al. Quelles consommations en prison? À partir de l'étude consommation de substances et médicaments au sein de populations carcérales (COSMOS). Therapies. 2018;73(6):577. doi:10.1016/j.therap.2018.09.022
Fernandes Pereira P, Simon C. Consommations de substances psycho-actives en milieu carcéral: étude qualitative rétrospective. Psychotropes. 2017;23(2):35-56. doi:10.3917/psyt.232.0035
Marzo JN, Rotily M, Meroueh F, et al. Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003-06). Addiction. 2009;104(7):1233-1240. doi:10.1111/j.1360-0443.2009.02558.x
Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128(1):4-8. doi:10.1111/bcpt.13492
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101. doi:10.1191/1478088706qp063oa
Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269-281. doi:10.1586/erp.10.30
Elger BS, Goehring C, Revaz SA, Morabia A. Prescription of hypnotics and tranquilisers at the Geneva prison's outpatient service in comparison to an urban outpatient medical service. Soz Praventivmed. 2002;47(1):39-43. doi:10.1007/BF01318404
Keller M, Ploton N. Vécu et perception des soins en milieu carcéral: étude quatitative auprès des personnes incarcérées à la maison d'arrêt de Grenoble-Varces. Université Joseph Fourier; 2014.
Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152-155. doi:10.18773/austprescr.2015.055
Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches: treatment of benzodiazepine dependence. Addiction. 2002;97(7):851-859. doi:10.1046/j.1360-0443.2002.00129.x
Hawkins EJ, Lott AM, Danner AN, et al. Primary care and mental health prescribers, key clinical leaders, and clinical pharmacist specialists' perspectives on opioids and benzodiazepines. Pain Med. 2021;22(7):1559-1569. doi:10.1093/pm/pnaa435
Wilson MG, Lee TC, Hass A, Tannenbaum C, McDonald EG. EMPOWERing hospitalized older adults to deprescribe sedative hypnotics: a pilot study. J am Geriatr Soc. 2018;66(6):1186-1189. doi:10.1111/jgs.15300
Williams J, Gingras MA, Dubé R, Lee TC, McDonald EG. Patient empowerment brochures to increase gabapentinoid deprescribing: protocol for the prospective, controlled before-and-after GABA-WHY trial. CMAJ Open. 2022;10(3):E652-E656. doi:10.9778/cmajo.20210302
Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. Jama. 2018;320(18):1889-1898. doi:10.1001/jama.2018.16131
Lerat MC, Cabelguenne D, Lassia J, Meunier F, Zimmer L. Impact of pharmacist and clinician dual intervention on prescribed benzodiazepines in prisoner patients: a retrospective study: impact of pharmacist intervention on prescribed benzodiazepines in prisoners. Fundam Clin Pharmacol. 2011;25(6):762-767. doi:10.1111/j.1472-8206.2010.00902.x
Reeves R. Guideline, education, and peer comparison to reduce prescriptions of benzodiazepines and low-dose quetiapine in prison. J Correct Health Care. 2012;18(1):45-52. doi:10.1177/1078345811421591